{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:55:16Z","timestamp":1767981316028,"version":"3.49.0"},"reference-count":16,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Neurol"],"abstract":"<jats:p>&lt;p&gt;Background: Leukocytoclastic vasculitis (LCV) is a small vessel vasculitis primarily affecting the skin, and its association with specific drugs is not widely documented. This case study explores the occurrence of LCV following the initiation of ocrelizumab, a monoclonal antibody used in the treatment of primary progressive multiple sclerosis (PPMS). Case Presentation: A 49-year-old Iranian female with PPMS developed lower limb edema and diffuse palpable purpura 1 week after starting ocrelizumab therapy. Skin biopsy confirmed LCV, showing vessel wall destruction, neutrophil infiltration, and fibrinoid necrosis. Laboratory tests revealed elevated inflammatory markers, including ESR 1 h: 52 and CRP: 52.8, supporting the diagnosis. The patient\u2019s symptoms improved after a course of intravenous methylprednisolone, and ocrelizumab was resumed without recurrence of skin lesions. This case highlights the need for vigilance in detecting drug-related vasculitis in ocrelizumab-treated patients. Conclusion: This case is the first reported instance of LCV associated with ocrelizumab in the treatment of multiple sclerosis. It underscores the need for awareness of potential drug-induced vasculitis in patients undergoing new or modified treatments and contributes to the growing understanding of adverse effects associated with ocrelizumab. &lt;\/p&gt;<\/jats:p>","DOI":"10.1159\/000548629","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:12:11Z","timestamp":1765357931000},"page":"125-133","source":"Crossref","is-referenced-by-count":1,"title":["First Reported Case of Ocrelizumab-Associated Leukocytoclastic Vasculitis in Primary Progressive Multiple Sclerosis: A Case Report"],"prefix":"10.1159","volume":"17","author":[{"given":"Mohammadali","family":"Nahayati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Farahnezhad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Khanmirzaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Khosravani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.5.2782"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy151"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000155050.03916.04"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282f5e08d"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq027"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.23732"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000563"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-021-02688-x"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7912"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004238"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006376"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.01.044"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2005.05.007"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v94.7.2217.419k02_2217_2224"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000051713"}],"container-title":["Case Reports in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000548629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:12:16Z","timestamp":1765357936000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000548629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000548629","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.30196852","asserted-by":"subject"}]},"ISSN":["1662-680X"],"issn-type":[{"value":"1662-680X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]}}}